Skip to content

Study · Animal study (in vivo) · rat · 2025

3 results

Impact of degradation in subcutaneous tissue and lymphatic fluid on absorption of Fc-fusion proteins following subcutaneous administration.

Yokoyama M, Suzuki E, Nakai D

Drug metabolism and pharmacokinetics17 Jul 2025Cited by 2 (Europe PMC)

PMID40912139 (opens in a new tab)DOI10.1016/j.dmpk.2025.101500 (opens in a new tab)PepBankPUB-40912139
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, dulaglutide bioavailability was 80.1% by the Fc/Fc method and 35.0% by the Protein/Fc method.

    In plain wordsIn rats, measured dulaglutide absorption differed between two assays.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedBioavailability by assay method
    Study

    ratn: not reported in source

    Rat absorption study
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Bioavailability
    80.1%
    Fc/Fc method
    Bioavailability
    35%
    Protein/Fc method

    Source sentences

    Summary
    BA of dulaglutide and romiplostim in rats were 80.1 % and 99.4 % by the Fc/Fc method, and 35.0 % and 55.5 % by the Protein/Fc method, respectively.
    2 context sentences
    Summary · context
    We established two measurement methods for each Fc-fusion protein: the Fc/Fc method, which recognizes the Fc region; and the Protein/Fc method, which recognizes both protein and Fc region.
    Title · context
    Impact of degradation in subcutaneous tissue and lymphatic fluid on absorption of Fc-fusion proteins following subcutaneous administration.

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 02LabNot a test of Dulaglutide (Trulicity) aloneIn vitro (cell-free)Mechanism

    In rat skin homogenates and lymphatic fluid, dulaglutide protein regions degraded.

    In plain wordsIn lab tests with rat skin material and lymph fluid, dulaglutide protein regions degraded.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableProtein region degradation
    Study

    ratn: not reported in source

    Skin homogenates and lymphatic fluid
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    In stability studies with rat skin homogenates and lymphatic fluid, degradation of the protein region for both dulaglutide and romiplostim was confirmed, which was inhibited by protease inhibitors.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 03LabNot a test of Dulaglutide (Trulicity) aloneIn vitro (cell-free)Mechanism

    In rat skin homogenates and lymphatic fluid, protease inhibitors inhibited dulaglutide protein-region degradation.

    In plain wordsIn lab tests with rat skin material and lymph fluid, protease inhibitors reduced dulaglutide breakdown.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseProtease inhibition of degradation
    Study

    ratn: not reported in source

    Skin homogenates and lymphatic fluid
    Comparator
    Without protease inhibitors
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    In stability studies with rat skin homogenates and lymphatic fluid, degradation of the protein region for both dulaglutide and romiplostim was confirmed, which was inhibited by protease inhibitors.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.